Print E-mail
Volume 38, Number 6, December 2005

Etanercept therapy in children with juvenile rheumatoid arthritis


Jeng-Juh Hung, Jing-Long Huang
Division of Allergy, Asthma and Rheumatology, Department of Pediatrics, Chang Gung Children's Hospital and Chang Gung University, Taoyuan, Taiwan

Received: September 22, 2004    Revised: March 28, 2005    Accepted: May 3, 2005   

 

Corresponding author:

Dr. Jing-Long Huang, Division of Allergy, Asthma and Rheumatology, Department of Pediatrics, Chang Gung Children's Hospital and Chang Gung University, Taoyuan, Taiwan. E-mail: long@adm.cgmh.org.tw This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

 



 

Methods:

Etanercept is an effective inhibitor of tumor necrosis factor that has shown a beneficial effect in patients with juvenile rheumatoid arthritis (JRA) that did not respond to other disease-modifying drugs. Here we report 3 patients with JRA who were refractory to traditional therapy; 1 with systemic JRA and 2 with polyarticular JRA. They received etanercept 0.4 mg/kg (maximum 25 mg) subcutaneously, twice a week for 3 months. The symptoms of arthritis improved significantly except that the patient with systemic JRA had disease flare-up during etanercept therapy. Two patients had upper respiratory tract infection during etanercept therapy and 1 suffered from seizure attack. The 2 patients with polyarticular JRA had disease flare-up within 2 months after etanercept was discontinued. This is the first report of etanercept treatment in JRA patients in Taiwan.

 



 

Key words:

Etanercept, juvenile rheumatoid arthritis, tumor necrosis factor-alpha



 



 

J Microbiol Immunol Infect 2005;38:444-446.